Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹æ±¤ÀÇ ÀÌÇà»óÇǼ¼Æ÷¾Ï ȯÀÚ¿¡¼­ E-cadherin ¹ßÇöÀÇ ÀÇÀÇ The Significance of E-cadherin Expression in Transitional Cell Carcinoma of the Bladder

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 9È£ p.1125 ~ 1131
¾ç»ó±¹, ÃÖÀçõ, ±èÈ«¼·,
¼Ò¼Ó »ó¼¼Á¤º¸
¾ç»ó±¹ (  ) 
°Ç±¹´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

ÃÖÀçõ (  ) 
°Ç±¹´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
±èÈ«¼· (  ) 
°Ç±¹´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
¿ì¸® ³ª¶ó¿¡¼­ ¹æ±¤ÀÇ ÀÌÇà»óÇǼ¼Æ÷¾ÏÀº ºñ´¢»ý½Ä°è¿¡¼­ ¹ß»ýÇÏ´Â ¾Ï Áß¿¡¼­ °¡Àå ÈçÇÑ
ÁúȯÀ¸·Î, Áø´Ü ´ç½Ã ¾à70%¿¡¼­´Â ¹æ±¤ ³»¿¡ ±¹ÇѵǾî Àִ ǥÀ缺 ¾ÏÀÌ°í, 15%Á¤µµÀÇ È¯
ÀÚ¿¡¼­ ħÀ±¼º ¾ÏÀ¸·Î Áø´ÜµÇ°í ÀÖÀ¸¸ç, Ç¥À缺 ¹æ±¤¾ÏÀÇ 40-80%¿¡¼­´Â °æ¿äµµÀýÁ¦¼ú ÈÄ¿¡
µµ Àç¹ßÇÏ°í, 5-30%¿¡¼­´Â ħÀ±¼º ÁúȯÀ¸·Î ÁøÇàµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ¹æ±¤¾ÏÀÇ Àç¹ß°ú
ÁøÇàÀ» ¿¹ÃøÇϱâ À§ÇØ Á¾¾ç º´±â¿Í ºÐÈ­µµ°¡ ÀÌ¿ëµÇ°í ÀÖÀ¸¸ç, ÇöÀçDNA ploidy, p53, Rb,
PDGF, VGF, Ki-67°ú cyclin D1 µîÀÇ »õ·Î¿î ¿¹ÈÄÀÎÀÚµéÀÌ ¿¬±¸ Áß¿¡ ÀÖ°í ÃÖ±Ù¿¡´Â ¾ÏÁ¾
ÀÇ Ä§À±¼º ¹× ÀüÀÌ¿Í °ü·ÃÇÏ¿© ¼¼Æ÷ºÎÂøºÐÀÚ°¡ Áß¿äÇÑ ÀÎÀڷμ­ ÀÎÁ¤¹Þ°í ÀÖ´Ù.
¼¼Æ÷ºÎÂøºÐÀÚ¿¡´Â integrin, cadherin°ú ImmunoglobulinÀ¸·Î ³ª´©¾î Áú ¼ö ÀÖÀ¸¸ç, ƯÈ÷
cadherinÀº ¼ö½Ê Á¾·ù°¡ ¹àÇôÁ® ÀÖ°í P(placental)-, N(neural)-°ú E(epithelial) cadherin¿¡
´ëÇÑ ¿¬±¸°¡ ¸¹ÀÌ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, ÀÌ Áß¿¡¼­ E-cadherinÀÌ ¹æ±¤ Á¶Á÷ÀÇ »óÇǼ¼Æ÷¿¡ Á¸
ÀçÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ°í, ±× ±â´ÉÀº Á¤»óÀûÀÎ Á¶Á÷ÀÇ ¹ÐÂø, ¼¼Æ÷ºÐÈ­ ¹× Á¶Á÷ÀÇ À¯Áö¿¡
Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ»Ó¸¸ ¾Æ´Ï¶ó ¼¼Æ÷ÀÌ µ¿°ú Á¶Àý ¹× ÀûÀÀ¿¡µµ °ü¿©ÇÑ´Ù. cadherinÀº ¸·Åõ°ú
¼º ´ç´Ü¹éÀ¸·Î Ä®½· ÀÇÁ¸ÀûÀÎ ¼ºÁúÀ» °®À¸¸ç, ´ëºÎºÐÀÌ ±ÕÀÏÇÏ°Ô ¼¼Æ÷°£ÀÇ °æ°è¿¡ Á¸ÀçÇϸç
¼¼Æ÷¿Í ±âÀú¸·ÀÇ °æ°è¿¡¼­´Â Á¸ÀçÇÏÁö ¾Ê°í, Á¾ ƯÀ̼ºÀ» °®À¸¸ç cateninÀ» ¸Å°³·Î ÇÏ¿© ´Ù
¸¥ ¼¼Æ÷ÀÇ cadherin°ú °áÇÕÇÏ°í, ¿©·¯ Àå±âÀÇ Á¾¾çÀÇ º´±â¿Í ºÐÈ­µµ¿¡ µû¶ó cadherin ¹ßÇöÀÌ
º¯È­ÇÑ´Ù°í ÇÏ¿© »õ·Î¿î ¾Ï ¿¹ÈÄÀÎÀڷμ­ ÀÎÁ¤¹Þ°í ÀÖ´Â ¹°ÁúÀÌ´Ù. ±×¸®°í Á¾¾ç Áúȯ¿¡ ÀÖ
¾î¼­ ÀüÀÌ´Â ¿ø¹ß Á¾¾ç¿¡¼­ ¼¼Æ÷ºÎÂøºÐÀÚÀÇ »óÈ£ ÀÛ¿ë°ú °ü·ÃÀÌ ÀÖÀ» °ÍÀ̶ó°í »ý°¢µÇ¾îÁö
´Âµ¥, ¿ø¹ß Á¾¾ç¿¡¼­ ¼¼Æ÷ºÎÂøºÐÀÚÀÇ ÀÌ»óÀ¸·Î ¾ß±âµÈ ¾Ï¼¼Æ÷ÀÇ À¯Âø·ÂÀÇ »ó½ÇÀº ¾ÏÁ¾ÀÇ Ä§
À±¼º°ú À¯ÁÖ¼¼Æ÷µé°ú °ü·ÃÀÌ ÀÖÀ» °ÍÀ̶ó »ý°¢µÇ¸ç, ±× Áß¿¡¼­µµ E-cadherinÀÇ Á߿伺ÀÌ ºÎ
°¢µÇ°í ÀÖ´Ù.
¿¹ÈÄ¿¡ À־ ¾Ï¼¼Æ÷ÀÇ Ä§À±·ÂÀº °áÁ¤ÀûÀÎ ¿ªÇÒÀ» ÇÏÁö¸¸ ±×°ÍÀ» °´°üÀûÀ¸·Î ÃøÁ¤ÇÒ ¼ö
ÀÖ´Â ¹æ¹ýÀÌ ¾ø´Â ½ÇÁ¤À̸ç, ¼¼Æ÷-±âÁú ºÎÂø°ú ¼¼Æ÷°£ À¯ÂøÀÇ °¨¼Ò ¹× ¼¼Æ÷»ç¸ÁÀÇ Áõ°¡ µî
ÀÇ ¿©·¯ °¡Áö ¿ä¼ÒµéÀÌ º¹ÇÕÀûÀ¸·Î ¿¬°üµÇ¾î ÀÖ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, cadherin¹ßÇöÀ»
ÀÌ¿ëÇÏ¿© °´°üÀûÀÌ°í Á¤·®ÀûÀ¸·Î ħÀ±·ÂÀ» ÃøÁ¤ÇÏ¿© ¹æ±¤¾ÏÀÇ ÁøÇà°ú Àç¹ßÀ» ¿¹»óÇÒ ¼ö ÀÖ
À» °ÍÀÌ´Ù.
ÀÌ¿¡ º» ½ÇÇè¿¡¼­´Â E-cadherinÀÇ ÀÓ»óÀû °¡Ä¡¸¦ ÃøÁ¤Çϱâ À§ÇÏ¿©, ¹æ±¤¾Ï Á¶Á÷¿¡¼­
E-cadherin¿¡ ´ëÇÑ ¸é¿ªÁ¶Á÷È­ÇÐÀû ¿¬±¸¸¦ ½ÃÇàÇÏ¿© E-cadherin¹ßÇö°ú Á¾¾çÀÇ º´±â, ºÐÈ­
µµ, Àç¹ß ¹× ÁøÇà°úÀÇ °ü°è¸¦ ºñ±³ ºÐ¼®ÇÏ¿´´Ù.

Purpose : To investigate the significance of E-cadherin expression in transitional cell
carcinoma of bladder, as the prognostic value.
Materials and Methods : We have analyzed its immunoreactivity in 41 transitional cell
carcinomas using a labelled streptavidin-biotin immunoperoxidase technique on the
formalin-fixed and the paraffin-embedded tissues. E-cadherin is a
Ca2+-dependent intracellular adhesion molecule of the epithelial tissue and
the urothelium. We determined the E-cadherin expression in bladder carcinoma using
immunohistochemical method and investigated relationship between pathological and
clinical data.
Results : The percentage of cases showing weak pattern was higher in cases with
high-grade or high-stage tumors as compared with those of low grade or low stage.
The E-cadherin was expressed in a normal membranous pattern in all control cases.
Abnormal E-cadherin expression was found in 8 of 20 superficial tumors and in 19 of
21 invasive tumors. Abnormal immunoreactivity was related to tumor differentiation and
stage. Eight of 13 well-differentiated tumors showed preservation of membranous
E-cadherin immunoreactivity, while 2 of 28 moderately and poorly differentiated tumors
demonstrated normal staining patterns.
Conclusions : We conclude that the loss of expression of E-cadherin in high grade or
high stage transitional cell carcinoma of bladder is associated with bladder wall invasion,
indicates metastasis, and may be clinical value in the assessment of prognosis.

Å°¿öµå

Transitional cell carcinoma; E-cadherin;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS